Verve Therapeutics has announced groundbreaking Phase 2 clinical trial results showing that a single, one-time CRISPR base-editing infusion can permanently lower high blood pressure, effectively curing hypertension in a majority of trial participants. The therapy, which targets a specific gene in the liver, represents a massive paradigm shift in cardiovascular medicine, moving away from daily symptom management toward permanent genetic cures.

To understand this breakthrough, think of your liver as a factory that produces a specific protein called angiotensinogen, which naturally raises your blood pressure. In people with severe hypertension, this factory is working in overdrive, forcing the heart to pump against massive resistance. Traditional blood pressure pills act like a temporary dam, blocking the protein for 24 hours before washing out of your system, which is why you have to take them every single day. Verve's CRISPR therapy acts like a genetic software update; it permanently edits the DNA inside the liver cells to turn the factory's power switch off, stopping the overproduction of the protein forever.

The data revealed that patients who received the single infusion maintained drastically lowered blood pressure for over two years without needing any additional medication. If this therapy receives full FDA approval in the coming years, it could eliminate the need for billions of daily pills taken globally, drastically reducing the rates of heart attacks, strokes, and kidney failure caused by medication non-compliance. It marks the dawn of an era where chronic cardiovascular diseases are cured with a single visit to the clinic.

Related Topics:

#Health#CRISPR#Genetics#Gene Editing#Hypertension#Cardiology#Verve Therapeutics#Medical Research
ayesha
ayeshaStaff Writer

Related Articles

Comments (0)

No comments yet. Be the first to share your thoughts!